Abstract
Although messenger RNA (mRNA) vaccines have established efficacy for prevention of severe SARS-CoV2 infection in the general population, their effectiveness in patients with malignancy, especially those on anti-neoplastic therapies, remains an area of open research. In order to better understand the risk of developing breakthrough SARS-CoV-2 infection and the outcomes associated with breakthrough infection for cancer patients, individual patient data from a curated outcomes database at the University of Kansas were retrospectively reviewed to determine the rate of breakthrough infection during an 8-month period encompassing the height of the delta variant surge. Although the rate of breakthrough infection in cancer patients after two doses of an mRNA vaccine remained low at 1.1%, hospitalization and death rates were 27 and 5%, respectively. Patients with hematologic malignancies, especially multiple myeloma, and those on anti-neoplastic therapy at the time of vaccination were found to be at higher risk for developing breakthrough infection.
Keywords: COVID; Hematologic malignancy; Oncology; SARS-CoV-2.
【저자키워드】 SARS-CoV-2., COVID, oncology, Hematologic malignancy, 【초록키워드】 SARS-CoV-2, Efficacy, Vaccine, vaccination, therapy, Hospitalization, mRNA vaccine, SARS-COV-2 infection, variant, risk, outcome, database, SARS-CoV2 infection, Myeloma, Multiple myeloma, mRNA, oncology, Research, Patient, Cancer patients, Effectiveness, Breakthrough infection, General population, university, Therapies, dose, Hematologic malignancy, malignancy, cancer patient, death rates, death rate, patient data, Height, Messenger RNA, higher risk, severe SARS, malignancies, hematologic, remained, determine, curated, 【제목키워드】 SARS-CoV-2,